Interventions that have been utilized to control seizures in people with epilepsy have been employed by the psychiatric community to treat a variety of disorders. The purpose of this review will be to give an overview of the most prominent uses of antiepileptic drugs (AEDs) and devices like the Vagus Nerve Stimulator (VNS) and Transcranial Magnetic Stimulation (TMS) in the treatment of psychiatric disease states. By far, the most prevalent use of these interventions is in the treatment of mood disorders. AEDs have become a mainstay in the effective treatment of Bipolar Affective Disorder (BAD). The U.S. Food and Drug Administration has approved the use of valproic acid for acute mania, and lamotrigine for BAD maintenance therapy. AEDs are also effectively employed in the treatment of anxiety and aggressive disorders. Finally, VNS and TMS are emerging as possibly useful tools in the treatment of more refractory depressive illness.
KetterTAManjiHKPostRM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol2003;23:484–495.
2.
BoylanLSDevinskyOBarryJJ. Psychiatric uses of antiepileptic treatments. Epilepsy Behav2002;3:S54–S59.
3.
BowdenCL. Treatment of bipolar disorder. In: SchatzbergAFNemeroffCB, (eds). Textbook of Psychopharmacology. 2nd ed.Washington, DC: American Psychiatric Press, Inc.; 1998: 733–746.
4.
KetterTAPostRMTheodoreWH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology1999;53:S53–S67.
5.
Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.
6.
KesslerRCBerglundPDernierOJinRKoretzDMerikangasKR. The epidemiology of Major Depressive Disorder, results from the National Comorbidity Survey Replication (NCS-R). JAMA2003;289(23): 3095–3105.
7.
SchatzbergAF. Bipolar disorder: Recent issues in diagnosis and classification. J Clin Psychiatry1998;59(6): 5–10.
8.
KesslerRCMcGonagleKAShanyangZ. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey. Arch Gen Psychiatry1994;51:8–19.
9.
McElroySLKeckPE. Diagnosis and treatment of rapid cycling states in bipolar disorder. In: YathamLNKusumakerVKutcherSP, (eds). Bipolar Disorder, A Clinicians Guild To Biological Treatments. New York: Brunner-Routledge; 2002; 33–57.
10.
CharneyDSBermanRMMillerHL. Treatment of depression. In: SchatzbergAFNemeroffCB, (eds). Textbook of Psychopharmacology. 2nd ed.Washington, DC: American Psychiatric Press, Inc.; 1998; 705–732.
11.
CalabreseJRSheltonMDRapportDJ. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord2001;67(1–3): 241–255.
12.
MacRitchieKGeddesJRScottJ. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev2003;1:1–48.
13.
FryeMAAltshulerLLSzubaMP. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psychiatry1996;57:17–21.
14.
SuppesTDennehyEBSwannAC. Texas Consensus Conference Panel on Medication Treatment of Bipolar D: Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry2002;63(4): 288–299.
15.
KeckPEJrMendlwiczJCalabreseJR. A review of randomized, controlled clinical trials in acute mania. J Affect Disord2000;59(suppl) 1:S31–S37.
16.
KeckPEJrMcElroySL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry2002;63(suppl10): 13–17.
17.
YathamLNKusumakarV.Anticonvulsants in treatment of bipolar disorder: A review of efficacy. In: YathamLNKusumakerVKutcherSP, (eds). Bipolar Disorder: A Clinicians Guild To Biological Treatments. New York: Brunner-Routledge; 2002: 201–240.
18.
LererBMooreNMeyendorffE. Carbamazepine versus lithium in mania: A double-blind study. J Clin Psychiatry1987;48(3): 89–93.
19.
EmrichHMAltmannHDoseM. Therapeutic effects of GABA-ergic drugs in affective disorders: A preliminary report. Pharmacol Biochem Behavior1983;19(2): 369–372.
20.
EmrichHMDoseMvon ZerssenD. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord1985;8(3): 243–250.
21.
MishoryAYaroslavskyYBersudskyY. Phenytoin as an antimanic anticonvulsant: A controlled study. Am J Psychiatry2000;157(3): 463–465.
22.
PandeACCrockattJGJanneyCA. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord2000;2(3 Pt 2): 249–255.
23.
FryeMAKetterTAKimbrellTA. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol2000;20(6): 607–614.
24.
YathamLNKusumakarVCalabreseJR. Third generation anticonvulsants in bipolar disorder: A review of efficacy and summary of clinical recommendations. J Clin Psychiatry2002;63(4): 275–283.
25.
ErfurthAGrunzeH.New perspectives in the treatment of acute mania: A single case report. Prog Neuro-Psychopharmacol Biol Psychiatry1998;22(6): 1053–1059.
26.
BerkM.Lamotrigine and the treatment of mania in bipolar disorder. Euro Neuropsychopharmacology1999;9(suppl) 4: S119–S123.
27.
IchimLBerkMBrookS.Lamotrigine compared with lithium in mania: A double-blind randomized controlled trial. Ann Clin Psychiatry2000;12(1): 5–10.
28.
AnandAOrenDABermanR. Lamotrigine treatment of lithium failure outpatient mania: a double blind placebo controlled trial. In: SoaresJGershonS (eds). 3rd International Conference on Bipolar Disorder; Pittsburgh, PA; 1999: 23.
29.
GrunzeHCNormannCLangoschJ. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry2001;62(6): 464–468.
30.
NormannCLangoschJSchaererLO. Treatment of acute mania with topiramate. Am J Psychiatry1999;156(12): 2014.
31.
PecuchPWErfurthA.Topiramate in the treatment of acute mania. J Clin Psychopharmacol2001;21(2): 243–244.
32.
GrunzeHErfurthAMarcuseA. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry1999;60(11): 759–762.
33.
KanbaSYagiGKamijimaK. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuro-Psychopharmacol Biol Psychiatry1994;18(4): 707–715.
34.
YathamLNCalabreseJRKusumakarV. Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord2003;5:85–97.
35.
BowdenCLCalabreseJRSachsG. Lamictal 606 Study G: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypo-manic patients with bipolar I disorder. Arch Gen Psychiatry2003;60(4):392–400.
36.
BowdenCLCalabreseJRMcElroySL. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry2000;57(5): 481–489.
37.
MuzinaDJEl-SayeghSCalabreseJR. Antiepileptic drugs in psychiatry: Focus on randomized controlled trial. Epilepsy Res2002;50(1–2): 195–202.
38.
CalabreseJRSheltonMDRapportDJ. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord2001;67:241–255.
39.
DunnerDLFieveRR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry1974;30:229–233.
40.
DenicoffKDSmith-JacksonEEDisneyER. Comparitive prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry1997;58:470–478.
41.
OkumaT.Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology1993;27:138–145.
42.
CalabreseJRSuppesTBowdenCL. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry2000;61(11):841–850.
43.
MarcotteD.Use of topiramate, a new antiepileptic as a mood stabalizer. J Affect Disord1998; 50; 245–251.
44.
CalabreseJRBowdenCLSachsGS. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry1999;60(2): 79–88.
45.
WinsbergMEDe GoliaSGStrongCM. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord2001;67(1–3): 207–212.
46.
PostRMUhdeTMRoy-ByrnePP. Antidepressant effects of carbamazepine. Am J Psychiatry1986;143:29–34.
47.
McIntyreRSManciniDAMcCannS. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single- blind study. Bipolar Disord2002;4(3):207–213.
48.
SteinacherLVandelPZullinoDF. Carbamazepine augmentation in depressive patients non-responding to citalopram: A pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol2002;12(3):255–260.
49.
StuppaeckCHBarnasCSchwitzerJ. Carbamazepine in the prophylaxis of major depression: A 5–year follow- up. J Clin Psychiatry1994;55(4): 146–150.
50.
KudohAIshiharaHMatsukiA.Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: A trial of off-on-off-on design. Clin J Pain1998;14(1): 61–65.
51.
DavisLLRyanWBryonA. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol2000;20(1): 1S–17S.
52.
NormannCHummelBScharerLO. Lamotrigine as adjunct to paroxetine in acute depression: A placebo- controlled, double-blind study. J Clin Psychiatry2002;63(4): 337–344.
53.
PandeACDavidsonJRJeffersonJW. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol1999;19(4): 341–348.
54.
LydiardRBMortonWAEmmanuelNP. Preliminary report: Placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacology Bull1993;29(2): 183–188.
55.
BlackDWWesnerRBowersW. A comparison of flu-voxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry1993;50(1): 44–50.
56.
SinghLFieldMJFerrisP. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology1996;127(1): 1–9.
57.
PandeACPollackMHCrockattJ. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol2000;20(4): 467–471.
58.
PostRMWeissSRSmithM. Kindling versus quenching: Implications for the evolution and treatment of posttraumatic stress disorder. Ann NY Acad Sciences1997;821:285–295.
59.
UpperSDavidsonJRGradyTA. Preliminary study of carbamazepine in post-traumatic stress disorder. Psycho-somatics1986;27(12): 849–854.
60.
WolfMEAlaviAMosnaimAD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings: Possible therapeutic effects of carbamazepine. Biol Psychiatry1988;23(6): 642–644.
61.
FordN.The use of anticonvulsants in posttraumatic stress disorder: Case study and overview. J Traum Stress1996;9(4): 857–863.
62.
ViolaJDitzlerTBatzerW. Pharmacological management of post-traumatic stress disorder: Clinical summary of a five-year retrospective study, 1990–1995. Military Med1997;162(9): 616–619.
HertzbergMAButterfieldMLFeldmanME. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry1999;45(9): 1226–1229.
68.
BerlantJvan KammenDP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J Clin Psychiatry2002;63(1): 15–20.
69.
BrannonNLabbateLHuberM.Gabapentin treatment for posttraumatic stress disorder. Canadian J Psychiatry - Rev Canadienne Psychiatrie2000;45(1): 84.
70.
MacLeodAD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol1996;16(2): 190–191.
71.
IancuIRosenYMosheK.Antiepileptic drugs in posttraumatic stress disorder. Clinical Neuropharmacology2002;25(4): 225–229.
72.
IwataYKotaniYHoshinoR. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry2000;61(7): 528–529.
73.
Cora-LocatelliGGreenbergBDMartinJ. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry1998;59(9): 480–481.
74.
DeltitoJA. Valproate pretreatment for the difficult-to-treat patient with OCD. J Clin Psychiatry1994;55(11): 500.
75.
StanfordMSHoustonRJMathiasCW. A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res2001;103(2–3): 193–203.
76.
BarrattESKentTABryantSG. A controlled trial of phenytoin in impulsive aggression. J Clin Psychopharmacol1991;11(6): 388–389.
77.
HollanderEDolgoff-KasparRCartwrightC. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry2001;62(7): 530–534.
78.
LindenmayerJPKotsaftisA.Use of sodium valproate in violent and aggressive behaviors: A critical review. J Clin Psychiatry2000;61(2): 123–128.
79.
SivalRCHaffmansPMJansenPA. Sodium valproate in the treatment of aggressive behavior in patients with dementia: A randomized placebo controlled clinical trial. Intl J Geriatr Psychiatry2002;17(6): 579–585.
80.
ChambersCABainJRosbuttumR. Carbamazepine in senile dementia and overactivity: A placebo controlled double blind trial. Med Sci1982;10:505–506.
81.
TariotPNErbRPodgorskiCA. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry1998;155(1): 54–61.
82.
DevarajanSDursunSM. Aggression in dementia with lamotrigine treatment. Am J Psychiatry2000;157(7): 1178.
83.
SchachterSC. The evolving place of vagus nerve stimulation therapy. Neurology2002;59:S1–S2.
84.
SchachterSC. Vagus nerve stimulation therapy summary: Five years after FDA approval. Neurology2002;59:S15–S20.
85.
HardenCL. The co-morbidity of depression and epilepsy: Epidemiology, etiology, and treatment. Neurology2002;59:S48–S55.
86.
RenfroeJBWhelessJW. Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology2002;59:S21–S25.
87.
HenryTR. Therapeutic mechanisms of vagus nerve stimulation. Neurology2002;59:S3–S14.
88.
HardenCLPulverMCRavdinLD. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav2000;1:93–99.
89.
KrahlSEClarkKBSmithDC. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia1998;39:709–714.
90.
SackeimHARushAJGeorgeMS. Vagus nerve stimulation (VNS) for treatment-resistant depression: Efficacy, side-efects and predictors of outcome. Neuropsychopharmacology2001;25:713–728.
91.
MarangellLBRushAJGeorgeMS. Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry2002;51:280–287.
92.
GeorgeMSNahasZBohningDE. Vagus nerve stimulation therapy: A research update. Neurology2002;59:S56–S61.
93.
McDonaldWMGreenbergBD. Electroconvulsive therapy in the treatment of neuropsychiatry conditions and transcranial magnetic stimulation as a pathophysiological probe in neuropsychiatry. Depress Anxiety2000;12:135–143.
94.
LamRWZisAPGoumenioukAD. Somatic treatments for bipolar disorder. In: YathamLNKusumakerVKutcherSP, (eds). Bipolar Disorder: A Clinician's Guide to Biological Treatments. New York: Brunner-Routledge; 2002: 241–254.
95.
GershonAADanonPNGrunhausL. Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry2003;160:835–845.
96.
TheodoreWH. Transcranial magnetic stimulation in epilepsy. Epilepsy Behav2001;2:S36–S40.
97.
GeorgeMSWassermannEMWilliamsWACallahanAKetterTA. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuro Report1995;6:1853–1856.
98.
GeorgeMSNahasZKozelFA. Mechanisms and the current state of transcranial magnetic stimulation. CNS Spectrums2003;8:496–514.
99.
MartinJLRBarbanojMJSchlaepferTE. Repetitive transcranial magnetic stimulation for the treatment of depression. Br J Psychiatry2003;182:480–491.
100.
GrunhausLDannonPNSchreiberS. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: An open study. Biol Psychiatry2000;47:314–324.
101.
GrunhausLSchreiberSDolbergOT. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry2000;47:314–324.
102.
NahasZKozelFALiX. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: A pilot study of acute safety and efficacy. Bipolar Disord2003;5:40–47.
103.
KaptsanAYaroslavskyYApplebaumJ. Right prefrontal TMS versus sham treatment of mania: A controlled study. Bipolar Disord2003;5:36–39.
